Dr Ciara O’Sullivan

Dr. O’Sullivan is an Assistant Professor of Medical Oncology focusing on clinical and translational research in breast cancer, currently employed at the Mayo Clinic in Rochester MN.

She is a prior recipient of a San Antonio Breast Cancer Symposium Clinical Scholars Scholarship (2013) Award, an American Society of Clinical Oncology (ASCO) Merit Award (2014), and an ASCO Career Development Award (2018). She is currently chair of an FDA registration trial, CompassHER2 RD (CompassHER2 Trials Examining Escalating and De-Escalating Therapy in HER2-Positive Breast Cancer: Optimizing Treatment in Residual Disease [CompassHER2 RD; NCT04457596; A011801]), and she has also led two other investigator-initiated trials: PROMISE (A Prospective Study to evaluate the role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer; NCT03281902) and ACCRU-BR01, A Phase I/II Trial of Abemaciclib and T-DM1 in Women and Men with HER2-Positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment with a Taxane, Trastuzumab and Pertuzumab (NCT04351230).

She is an ASCO Career Conversations Mentor and serves on the Alliance for Clinical Trials in Oncology (ALLIANCE) breast committee, as well as on the Mayo Clinic Institutional Review Board (IRB). She is also a reviewer for several journals including Breast Cancer Research and Treatment and Clinical Cancer Research.